Drug Discovery & Development |
Amgen Publishes Asthma Drug Proof-of-Concept in NEJM
Drug Discovery & Development Amgen announced that The New England Journal of Medicine (NEJM) published positive results from a Phase 1 study adding to the growing body of evidence that inhibiting thymic stromal lymphopoietin (TSLP) could be beneficial in the treatment of asthma. Novel Antibody Demonstrates Promise against Asthma Amgen drug for allergy asthma shows promise in early tests Novel Biologic Promising for Allergic Asthma |
View full post on asthma – Google News